Aligos Therapeutics (ALGS) FCF Margin (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed FCF Margin for 5 consecutive years, with 12866.86% as the latest value for Q4 2025.
- For the quarter ending Q4 2025, FCF Margin fell 1355586.0% year-over-year to 12866.86%, compared with a TTM value of 3774.15% through Dec 2025, down 1277560.0%, and an annual FY2025 reading of 3774.15%, up 2043932.0% over the prior year.
- FCF Margin was 12866.86% for Q4 2025 at Aligos Therapeutics, down from 3285.43% in the prior quarter.
- Across five years, FCF Margin topped out at 688.99% in Q4 2024 and bottomed at 105794.74% in Q3 2024.
- Average FCF Margin over 5 years is 8012.03%, with a median of 1416.04% recorded in 2024.
- The sharpest move saw FCF Margin crashed -10485063bps in 2024, then soared 10250931bps in 2025.
- Year by year, FCF Margin stood at 10304.09% in 2021, then soared by 99bps to 121.33% in 2022, then tumbled by -389bps to 593.3% in 2023, then soared by 216bps to 688.99% in 2024, then tumbled by -1967bps to 12866.86% in 2025.
- Business Quant data shows FCF Margin for ALGS at 12866.86% in Q4 2025, 3285.43% in Q3 2025, and 1606.63% in Q2 2025.